@article{b2bc25a79cf84068af4e7f71717b4ddd,
title = "Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice",
abstract = "The MATRix chemoimmunotherapy regimen is highly effective in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system (PCNSL). However, nothing is known about its feasibility and efficacy in everyday practice, where patients are more often older/frailer than those enrolled in clinical trials. We conducted a retrospective study addressing tolerability/efficacy of MATRix in 156 consecutive patients with newly diagnosed PCNSL treated outside a clinical trial. Median age and ECOG Performance Status of considered patients were 62 years (range 28–78) and 2 (range 0–4). The overall response rate after MATRix was 79%. Nine (6%) treatment-related deaths were recorded. After a median follow-up of 27.4 months (95% confidence interval [CI] 24.4–31.9%), the two-year progression-free and overall survival were 56% (95% CI 48.4–64.9%) and 64.1% (95% CI 56.7–72.5%) respectively. Patients not eligible for the IELSG32 trial were treated with lower dose intensity and had substantially worse outcomes than those fulfilling inclusion criteria. This is the largest series of PCNSL patients treated with MATRix outside a trial and recapitulates the IELSG32 trial outcomes in the non-trial setting for patients who fit the trial criteria. These data underscore the feasibility and efficacy of MATRix as induction treatment for fit patients in routine practice.",
keywords = "IELSG32 trial, induction treatment, MATRix regimen, primary diffuse large B-cell lymphoma of the central nervous system, routine clinical practice",
author = "Elisabeth Schorb and Fox, {Christopher P.} and Benjamin Kasenda and Kim Linton and Nicolas Martinez-Calle and Teresa Calimeri and Slavisa Ninkovic and Eyre, {Toby A.} and Tom Cummin and Jeffery Smith and Deborah Yallop and {De Marco}, Beatrice and Mauro Krampera and Stefan Trefz and Lorella Orsucci and Alberto Fabbri and Gerald Illerhaus and Kate Cwynarski and Ferreri, {Andr{\'e}s J.M.}",
note = "Funding Information: We would like to acknowledge support from Amy Beech, database manager at NUH (supported by grants from Gilead, Roche, Abbvie). Funding Information: The following potential conflicts of interest were reported by the authors: ES: research funding and consultancy fees from Riemser. CPF: research funding, consultancy fees and travel support from Roche and Adienne. BK: Travel support from Riemser, consultancy for Roche, research Grant from Roche/AbbVie. TC: research funding from Roche. TAE: honorarium from Roche. JS: consultancy fees and travel support from Abbvie. GI: research funding and consultancy fees from Riemser and Roche. KC: research funding, consultancy fees and travel support from Roche and Adienne. AJMF: research funding from Roche and Celgene, consultancy fees from Gilead and Celgene and travel support from Roche, Gilead and Adienne. Publisher Copyright: {\textcopyright} 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = jun,
day = "1",
doi = "10.1111/bjh.16451",
language = "English",
volume = "189",
pages = "879--887",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",
}